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Identity 
Note: B-cell NHL include a number of 
clinicopathologic subsets of lymphoid neoplasms 
having heterogeneous features. This situation is 
reflected by variations in the classification systems that 
were proposed over the last decade. Cytogenetic 
findings were recognized to help defining a rationale 
biologic ground for the nosologic classification of
lymphomas.  
An outlook of the salient cytogenetic entities in this 
spectrum of disorders is presented herein; a complete 
illustration of the cytogenetic profile of each disea e is 
provided in specific cards. Unless otherwise specified 
the WHO classification system will be used.  
Legend for immunophenotypes (below): +: positive in 
>90% of the cases; +/-: positive in more than 50% of 
the cases; -/+: positive in less than 50% of cases; -: 
positive in <10% of the cases; pan-B markers include 
CD19; CD20; CD79a; R = rearranged; sIg: surface 
immunoglobulins; cyIg: cytoplasmic Ig; IgV genes: 
genes encoding for the variable portion of the Ig. 
Clinics and pathology 
Disease 
Small lymphocytic lymphoma (SLL) 
Phenotype/cell stem origin 
Histologic subset and Immunophenotype: Pan-B+; 
CD5+; CD23+; CD10-; sIgM+ faint. 
Putative cell of origin: CD5+ virgin B-cell with 
germline IgV genes (as was recently demonstrated to 
be the case with chronic lymphocytic leukemia, the 
leukemic counterpart of SLL, it is likely that part of the 
cases may derive from post-germinal centre quiescent 
B-cells that harbour hypermutated IgV genes). 
Clinics 
Indolent disease; 
Leukemic involvement by lymphoid cells, including 
prolymphocytes and/or paraimmunoblasts 
Splenomegaly. 
Cytogenetics 
del(6)(q21-23) (20-30% of the cases). 
Disease 
Lymphoplasmacytic lymphoma 
Phenotype/cell stem origin 
Histologic subset and Immunophenotype: Pan-B+; 
CD5-; CD10-; cyIgM+. 
Putative cell of origin: Peripheral B-lymphocyte 
transforming into plasma cell with mutated IgV genes 
and ongoing mutations. 
Clinics 
Indolent low-grade disease, with possible clinical 
and/or histologic progression. 
Cytogenetics 
t(9;14)(p13;q32) PAX5/IgH (50% of cases). 
Disease 
Follicle centre cell lymphoma 
Phenotype/cell stem origin 
Histologic subset and Immunophenotype: Pan-B+; 
CD10+/-; CD5-; sIg+. Putative cell of origin: 
Centrocytes / centroblasts of germinal centre origin 
with somatic hypermutation of the IgV genes and 
ongoing mutations (antigen driven stimulation). 










Indolent. Advanced stages predominate. 
Conflicting data as to the prognostic significance of the 
t(14;18)/BCL2. 
Cytogenetics 
t(14;18)(q32;q21) / BCL2 Rearr (70-80% of cases). 
Disease 
Diffuse large cell lymphoma 
Phenotype/cell stem origin 
Histologic subset and Immunophenotype: CD19+; 
CD22+; CD10-/+; SIg+. 
Putative cell of origin: Large transformed B-cells 
harbouring somatic hypermutation of the Ig genes 
(ongoing mutations in some cases). 
Clinics 
Usually aggressive. 
Immunoblastic lymphoma (Kiel classification) do 
worse than centroblastic lymphomas. 
No convincing demonstration that any "primary" 
cytogenetic / molecular defect has prognostic 
significance; complex karyotype confers a shorter 
survival. 
Cytogenetics 
t(14;18) and p53 mutations (20% of the cases). 
t(3;V)(q27;V)/ BCL6 Rearr (6-30% of cases (% 
variations depending on detection methods: molecular 
genetics and FISH more sensitive that conventional 
cytogenetics)). 
Or variants c-MYC Rearr (7-10% of cases). 
Disease 
Burkitt's lymphoma 
Phenotype/cell stem origin 
Histologic subset and Immunophenotype: Pan-B+; 
TdT-; CD10+; CD5-; sIgM+. 
Putative cell of origin: Peripheral B-cells that have 
encountered the antigen and harbours somatic 
hypermutation of the Ig genes. 
Clinics 
Extremely aggressive disease. 
Specific treatment mandatory. 
Cytogenetics 
Or variants / c-MYC R earr (80% of the cases). 
Disease 
Burkitt-like lymphoma 
Phenotype/cell stem origin 
Histologic subset and Immunophenotype: Pan-B+; 
TdT-; CD10-/+ CD5-; sIg+. 
Putative cell of origin: Peripheral B-cells that have 
encountered the antigen. 
Clinics 
Aggressive disease. 
Cases with dual 8;14 and 14;18 translocations have a 
worse outcome (data requiring confirmation -1 study 
only). 
Cytogenetics 
t(8;14) or variants (25% of cases). 
t(8;14)+ t(14;18) (30% of cases). 
Disease 
Mantle cell lymphoma 
Phenotype/cell stem origin 
Histologic subset and Immunophenotype: Pan-B +; 
CD5+; CD23-; CD10-/+; sIgM+ bright. 
Putative cell of origin: CD5+ B-cells of the follicle 
mantle having germline IgV gene sequences. 
Clinics 
Advanced stages predominate. 
Response to chemotherapy often unsatisfactory. 
Short survival. 
Complex karyotype carries an unfavourable prognostic 
significance. 
Cytogenetics 
t(11;14)(q13;q32)/BCL1 Rearr (50-90%) (molecular 
genetic methods have limited application due to 
variability of breakpoints; FISH is the most sensitive 
technique). 
Disease 
Marginal zone B-cell lymphoma (MZBCL) 
Phenotype/cell stem origin 
Histologic subset and Immunophenotype: pan-B+; 
CD5-/+; CD10-; CD23-; CD11c+/-; cyIg + (40% of the 
cells), sIgM+ bright; sIgD-). 
Putative cell of origin: Marginal zone lymphocytes 
harbouring hypermutated IgV genes. 
Cytogenetics 
t(11;18)(q21;q21) PI2/MLT fusion (30-50% of the low-
grade MALT): Extra-nodal low-grade MALT 
lymphoma; indolent disease. 
t(1;14)(p21;q32): Extra-nodal MALT lymphoma. 
del(7)(q22-31) (40% of the cases): Splenic MZBCL. 
+3/+3q (30-70% of the cases): Nodal, extra-nodal and 
splenic MZBCL. 
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